Study of High Efficient Killing Cell Therapy for Advanced NSCLC

The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer

Trial Details

NCT ID
NCT03193567
Phase
PHASE1
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HEKT cell
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Male or female patients' age from 18 years to 70 years.
  • Patients who have a life expectancy of at least 3 months.
  • pathologically confirmed non-small cell lung cancer.
  • failed in previous standard chemotherapy and targeted therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →